<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T20:45:25Z</responseDate><request verb="GetRecord" identifier="oai:uwspace.uwaterloo.ca:10012/15515" metadataPrefix="dim">https://dspacemainprd01.lib.uwaterloo.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:uwspace.uwaterloo.ca:10012/15515</identifier><datestamp>2025-03-26T23:36:41Z</datestamp><setSpec>com_10012_9936</setSpec><setSpec>com_10012_1</setSpec><setSpec>col_10012_9947</setSpec><setSpec>col_10012_6</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Wong, William W.L.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" authority="b98d8992-cff8-4063-8d79-9a62525d4d65" confidence="600">Ellis, Kristina</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2020-01-21T17:12:07Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2020-01-21T17:12:07Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2020-01-21</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted">2019-12-23</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/10012/15515</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en">Background/Aim: &#xd;
Chimeric antigen receptor (CAR) T-cell therapy is a novel cell therapy for treating hematological cancers including multiply relapsed large B-cell lymphoma in adults. Although for some patients it can produce long-term remission who would have otherwise run out of treatment options, it is very expensive, costing $373,000 U.S. dollars per patient. There are also other additional hospital costs related to management of severe adverse events. The first two Health Canada approved CAR T-cell therapy products were reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH) and recommended for funding. Because CAR T-cell therapies have not been administered before in Canadian hospitals, there are certain logistical concerns with implementation that are unique. &#xd;
&#xd;
The first aim of this thesis is to describe processes of developing CAR T-cell therapy and administering it to patients, as well as describe the challenges to implementation and considerations for long-term sustainability of cell and gene therapy in Canada. The second aim is to evaluate the cost-effectiveness of axicabtagene ciloleucel, a CAR T-cell therapy for treating adult lymphoma patients, compared to salvage chemotherapy.&#xd;
&#xd;
Methods: &#xd;
A qualitative interview study was conducted with 13 CAR T-cell therapy stakeholders including scientists, clinicians, and policy-makers in Canada. Questions were asked related to CAR T-cell therapy development, treating patients, challenges to implementation, and suggestions for logistical planning at the healthcare system level.&#xd;
&#xd;
A partitioned survival model was developed in TreeAge Pro Software from a Canadian public payer perspective. Patients with large B-cell lymphomas were modeled and their health outcomes from being treated with axicabtagene ciloleucel or salvage chemotherapy were extrapolated over a lifetime time horizon. The cost-effectiveness was evaluated by the incremental cost-effectiveness ratio.&#xd;
&#xd;
Results: &#xd;
The results from the qualitative interviews were summarized into 4 main themes: novel, patient characteristics and experiences, processes from “bench to bedside”, and future state of CAR T-cell therapy in Canada, including both challenges and recommendations to ensure sustainability.&#xd;
&#xd;
The ICER generated for the cost-effectiveness analysis was $170,380 per QALY. At a willingness-to-pay threshold of $150,000 per QALY, CAR T-cell therapy is not cost-effective. There is some uncertainty in the long-term efficacy of CAR T-cell therapy and in the cost of CAR T-cell therapy.&#xd;
&#xd;
Conclusions: &#xd;
Valuable perspectives from CAR T-cell therapy stakeholders on the current and future state of CAR T-cell therapy were highlighted from a Canadian perspective. In addition, a reduction in price of CAR T-cell therapy and reduced uncertainty through collection of long-term health outcomes can improve the cost-effectiveness to ensure value-for-money.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en">en</dim:field>
   <dim:field mdschema="dc" element="publisher" lang="en">University of Waterloo</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">CAR T-cell therapy</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">cost-effectiveness</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">qualitative</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">large b-cell lymphoma</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">economic evaluation</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Canada</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Interviews</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">chimeric antigen receptor T-cell therapy</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">axicabtagene ciloleucel</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">partitioned survival model</dim:field>
   <dim:field mdschema="dc" element="title" lang="en">Cost-effectiveness of Chimeric Antigen Receptor T-cell Therapy for Treating Large B-cell Lymphoma Patients in Canada</dim:field>
   <dim:field mdschema="dc" element="type" lang="en">Master Thesis</dim:field>
   <dim:field mdschema="dc" element="pending">false</dim:field>
   <dim:field mdschema="uws-etd" element="degree" qualifier="department" lang="en">School of Pharmacy</dim:field>
   <dim:field mdschema="uws-etd" element="degree" qualifier="discipline" lang="en">Pharmacy</dim:field>
   <dim:field mdschema="uws-etd" element="degree" qualifier="grantor" lang="en">University of Waterloo</dim:field>
   <dim:field mdschema="uws-etd" element="degree" lang="en">Master of Science</dim:field>
   <dim:field mdschema="uws" element="contributor" qualifier="advisor">Wong, William W.L.</dim:field>
   <dim:field mdschema="uws" element="contributor" qualifier="affiliation1" lang="en">Faculty of Science</dim:field>
   <dim:field mdschema="uws" element="published" qualifier="city" lang="en">Waterloo</dim:field>
   <dim:field mdschema="uws" element="published" qualifier="country" lang="en">Canada</dim:field>
   <dim:field mdschema="uws" element="published" qualifier="province" lang="en">Ontario</dim:field>
   <dim:field mdschema="uws" element="typeOfResource" lang="en">Text</dim:field>
   <dim:field mdschema="uws" element="peerReviewStatus" lang="en">Unreviewed</dim:field>
   <dim:field mdschema="uws" element="scholarLevel" lang="en">Graduate</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>